Postoperative Abdominal Wall Wound Complications, Surgical Wound Infection, Surgical Wound Dehiscence, Mesh-Associated Wound Complications
Conditions
Keywords
Negative Pressure Wound Therapy, Arterial Stiffness, Aortic Pulse Wave Velocity, Arteriograph, Abdominal Wall, Wound Healing, Wound Volumetry, Systemic Inflammation, C-Reactive Protein
Brief summary
WALLAS is a small observational study of 30 adults with complex wounds in the abdominal wall after surgery. All participants will receive negative pressure wound therapy (NPWT) because their treating team considers it appropriate. This treatment uses a sealed dressing connected to a suction device. The study will not decide which treatment participants receive or change their usual care. The main aim is to find out how the stiffness of the large arteries changes during treatment. Researchers will also examine whether larger reductions in wound size and inflammation are linked to larger reductions in artery stiffness. An upper-arm cuff device will estimate artery stiffness by measuring how quickly pressure waves travel along the aorta, the body's main artery. Measurements are planned before treatment starts, around day 5, and when the first course of NPWT ends. Blood pressure will be taken into account when interpreting the results. During planned dressing changes, researchers will record wound depth and, when safe and technically possible, measure the wound cavity using sterile saline. Photographs will document the wound. Results from routine blood tests will provide information about inflammation; no extra blood samples are required for research. Wound recovery and further treatment will be followed for about six months after NPWT starts. The study will also assess how practical and safe the measurement procedures are. Because there is no comparison group, it cannot determine whether NPWT itself causes any changes in artery stiffness.
Detailed description
This prospective, single-center observational pilot examines whether changes in local wound burden and systemic inflammatory activity are accompanied by changes in arterial stiffness during clinically indicated negative pressure wound therapy (NPWT). The biological hypothesis is that greater reductions in wound-cavity volume and inflammatory burden are associated with greater reductions in aortic pulse wave velocity (PWVao). Treatment decisions, including NPWT settings, dressing-change intervals, debridement, antimicrobial treatment and reconstruction, remain the responsibility of the clinical team. Day 0 is the recorded date and time of first NPWT activation. Baseline vascular assessment (T0) must be completed within the preceding 60 minutes and before foam placement. T1 targets day 5, with an acceptable window of days 3-7. The T2 vascular assessment is scheduled within 24 hours before or after clinician-documented cessation of the first NPWT episode and before planned definitive wound closure. Cessation may occur for any reason and is not assumed to indicate healing; the actual treatment duration and reason for cessation are recorded. Temporary interruptions do not end the episode, and a later restart is a subsequent episode. Clinical follow-up targets day 180 after first activation, with an acceptable window of days 150-210. Optional follow-up vascular measurements are analyzed separately. Core vascular assessments use the Arteriograph TL2 under standardized awake, supine conditions after at least 10 minutes of rest, before dressing removal, painful wound manipulation or procedural sedation. Necessary routine analgesia is permitted and documented. Each session averages the first three valid acquisitions for each outcome, with a maximum of five attempts. Technical validity is assessed separately for PWVao and native aortic augmentation index. Nonstandard or out-of-window measurements are documented and analyzed separately rather than substituted for core assessments. The principal quantitative wound measure is operationally defined saline-fill wound-cavity volume. During the corresponding clinical encounter, sterile 0.9% saline is instilled after clinically indicated cleansing or debridement and before foam placement or closure. The cumulative volume required to reach a predefined filling endpoint is recorded. Measurements are omitted when filling is unsafe or leakage, communication with a body cavity or fistula, trapped air or an unreliable endpoint prevents valid assessment. Debridement, mesh procedures and other interventions that alter wound geometry are recorded because volume change can reflect both healing and surgical alteration. Photographs provide supportive documentation; quantitative two-dimensional planimetry is not required. Routine C-reactive protein (CRP), albumin and available complete blood count results are paired with vascular measurements using the closest sample collection time within 24 hours before or after assessment; ties favor the earlier sample. No additional research blood sampling is required. Operation and source-control timing, hemodynamic treatments, renal status, temperature, infection status, pain and analgesia are recorded to support interpretation of concurrent recovery. The primary analysis uses a random-intercept mixed model with categorical visit and separate within-person and between-person mean arterial pressure components. The main estimate is the pressure-adjusted T2-minus-T0 PWVao difference, accompanied by unadjusted paired changes. A supportive model uses actual elapsed days. Two prespecified secondary regressions relate T2-minus-T0 PWVao change separately to percentage wound-volume reduction and signed CRP change, each adjusted for change in mean arterial pressure. Percentage volume reduction requires valid same-encounter vascular-volume pairs at both visits and a positive baseline volume. Effect estimates and 95% confidence intervals are emphasized. Technical feasibility, measurement safety and completeness of serial assessments are reported separately. Missing measurements and their reasons are documented, with complete T0-T2 paired summaries provided alongside the longitudinal analysis. The study characterizes temporal changes and associations during clinical recovery; it cannot isolate an NPWT-specific causal effect or directly establish a local vascular mechanism.
Interventions
Negative pressure wound therapy delivered through a sealed wound dressing connected to a negative-pressure system. The treating clinical team selects the device, dressing, pressure settings, mode, dressing-change intervals and treatment duration according to clinical need. NPWT is an observed routine-care treatment and is not assigned or modified by the research protocol. Actual treatment characteristics and changes are recorded.
Sponsors
Study design
Eligibility
Inclusion criteria
* Age 18 years or older. * Clinically indicated negative pressure wound therapy (NPWT) for a postoperative abdominal wall wound complication. * At least one predefined complexity feature: mesh infection or exposure, purulent drainage, a deep wound cavity, tunneling, undermining, or fascial dehiscence after source control with protected viscera. * Hemodynamic stability sufficient for arterial stiffness measurement. * Written informed consent. * Willingness to undergo serial study assessments. There is no minimum wound surface-area threshold. The term "major" is an operational study definition, not an externally validated severity category. Following emergency surgery, enrollment is permitted only after source control and once the patient is stable for repeated vascular assessment.
Exclusion criteria
* NPWT for a non-abdominal wall wound. * NPWT primarily for temporary open-abdomen management. * Active uncontrolled bleeding. * Untreated osteomyelitis in the wound region. * Malignant wound bed. * Unprotected major vessel or exposed organ. * Uncontrolled intra-abdominal sepsis. * Severe hemodynamic instability or vasopressor requirement. * A fixed bilateral upper-arm contraindication to cuff-based oscillometric measurement present before enrollment. * Inability or unwillingness to provide informed consent. Fascial dehiscence may be included after source control when viscera are protected and NPWT targets the abdominal wall wound rather than temporary open-abdomen closure. Failure to obtain interpretable arterial stiffness recordings after enrollment is documented in descriptive feasibility reporting and is not used as a post hoc exclusion criterion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in aortic pulse wave velocity (PWVao) from baseline to cessation of the index NPWT episode | T0: within 60 minutes before first NPWT activation; T1: day 5 (days 3-7); T2: within 24 hours before or after cessation of the index NPWT episode (variable treatment duration). | Change in aortic pulse wave velocity (PWVao), measured in m/s using the Arteriograph TL2. Each standard-condition session is the mean of the first three valid PWVao acquisitions. The primary estimate is the mean arterial pressure (MAP)-adjusted T2-minus-T0 difference, with a 95% confidence interval, from a random-intercept mixed model incorporating T0, T1 and T2, categorical visit, and separate within-person and between-person MAP components. Observed unadjusted T0-T2 paired changes will also be reported. A negative change indicates lower measured arterial stiffness. T0 precedes foam placement. T2 is assessed before planned definitive closure and reflects cessation of the index NPWT episode for any reason, not necessarily wound healing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Association between PWVao change and percentage wound-cavity volume reduction | Vascular T0: within 60 minutes before first NPWT activation; vascular T2: within 24 hours before or after index-episode cessation. Volume is measured at the corresponding encounters, before definitive closure. Treatment duration varies. | Prespecified Model A coefficient relating T2-minus-T0 PWVao change (m/s) to percentage wound-cavity volume reduction (PVR), adjusted for T2-minus-T0 mean arterial pressure (MAP) change. PVR = 100 x (V0 - V2)/V0, using saline-fill volumes in mL. Report m/s per 10-percentage-point greater PVR, with 95% CI and a supplementary nominal P value when estimable. Require standard awake, interpretable T0-T2 vascular pairs, matched MAP, and valid same-encounter vascular-volume pairs at both visits with V0 \> 0. Retain negative PVR and valid pairs flagged for debridement or other wound-altering procedures. Missing or unmeasurable volumes are not assigned zero or 100% reduction. Fit only with sufficient predictor variation, a full-rank design, positive residual degrees of freedom and finite standard errors and confidence intervals, as prespecified; otherwise report individual data without a regression estimate. |
| Change in native aortic augmentation index (AIxao) | T0: within 60 minutes before first NPWT activation; T1: day 5 (days 3-7); T2: within 24 hours before or after cessation of the index NPWT episode, before planned definitive closure. Treatment duration varies. | Native aortic augmentation index (AIxao) measured using the Arteriograph TL2 at T0, T1 and T2. Each session value is the mean of the first three valid AIxao acquisitions, with technical validity assessed independently of PWVao. Native values are expressed as percentages and changes as percentage points. The main contrast is the T2-minus-T0 difference, adjusted for concurrent heart rate using the prespecified longitudinal mixed model, with a 95% confidence interval. Heart rate is obtained from the same acquisitions used for AIxao. No conversion to AIx at a standardized heart rate of 75 beats/min is performed. |
| Percentage reduction in saline-fill wound-cavity volume | T0, T1 (target day 5, days 3-7) and T2 wound assessments in the same encounters as the corresponding core vascular recordings; main volume comparison T0 to T2 at index-episode cessation, with variable treatment duration. | Arithmetic mean of patient-specific percentage volume reductions (PVR), each 100 x (V0 - V2)/V0, with a two-sided t-based 95% CI when at least two valid pairs permit calculation. This is not the ratio of group mean volumes. Report n, SD, median and IQR as supporting summaries. Use valid same-encounter saline-fill volumes and V0 \> 0. Negative PVR is retained. Debridement, mesh procedures and deliberate reopening are flagged. No reproducibly fillable residual cavity or loss of the operational filling endpoint during healing is a distinct reason for missing volume, not an assumed zero; a closed wound also has no unmeasured zero. T1 is supportive. The PWVao-PVR association is specified as a separate secondary outcome. |
| Change in C-reactive protein concentration | Routine blood samples within 24 hours before or after T0, T1 (target day 5, days 3-7) and T2 core vascular assessments; main comparison T0 to T2 at index-episode cessation, with variable treatment duration. | Arithmetic mean signed T2-minus-T0 CRP change in mg/L on the raw scale, with a two-sided t-based 95% CI when at least two valid pairs permit calculation. Report n, SD, median and IQR as supporting summaries; negative change indicates a decrease. Select the closest routine collection by absolute time within +/-24 hours of each vascular assessment; ties favor the earlier sample. Record collection times and signed intervals. Change and Model B require two distinct selected blood collection events; reused samples make change missing. Do not substitute another sample to force a pair or draw extra research blood. T1 is supportive. Secondary Model B relates PWVao change to signed CRP change/10 and MAP change, with the raw-scale slope in m/s per 10 mg/L higher signed CRP change, 95% CI and a supplementary nominal P value when estimable. It is an analysis, not an additional outcome. |
Countries
Hungary